Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

117.00USD
3:59pm EST
Change (% chg)

$2.71 (+2.37%)
Prev Close
$114.29
Open
$115.14
Day's High
$117.98
Day's Low
$115.12
Volume
892,907
Avg. Vol
645,004
52-wk High
$140.76
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Alexion Opposes Claims Against Co Filed By Chugai Pharmaceutical
Friday, 16 Nov 2018 06:40am EST 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::ALEXION - RESPONDING TO COMPLAINT FILED AGAINST CO BY CHUGAI PHARMACEUTICAL, CO TO OPPOSE CLAIMS & TO PROCEED WITH BUSINESS PLANS FOR ALXN1210.  Full Article

Temasek Holdings (Private) Ltd Dissolves Share Stake In Walt Disney, Amgen and Biogen
Wednesday, 14 Nov 2018 06:30am EST 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN WALT DISNEY CO - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN AMGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN BIOGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 18.5 PERCENT TO 1.2 MILLION SHARES.TEMASEK HOLDINGS (PRIVATE) LTD REPORTS SHARE STAKE OF 4.5 MILLION SHARES IN FARFETCH LTD.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Alexion Q3 NON-GAAP Earnings Per Share $2.02
Wednesday, 24 Oct 2018 06:35am EDT 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS THIRD QUARTER 2018 RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $2.02.Q3 GAAP EARNINGS PER SHARE $1.47.Q3 REVENUE $1.027 BILLION VERSUS I/B/E/S VIEW $1.02 BILLION.Q3 EARNINGS PER SHARE VIEW $1.74 -- THOMSON REUTERS I/B/E/S.ANNOUNCED AGREEMENT TO ACQUIRE SYNTIMMUNE AND COLLABORATION WITH DICERNA.UPDATED 2018 FULL-YEAR GUIDANCE.SEES 2018 REVENUE $4,020 MILLION TO $4,050 MILLION.ALEXION PHARMACEUTICALS - SEES 2018 ADJUSTED EARNINGS PER SHARE $7.45 TO $7.60.ALEXION PHARMACEUTICALS - EXPECTS TO INCUR ADDITIONAL RESTRUCTURING EXPENSES IN 2018 OF ABOUT $125 MILLION RELATED TO CO'S 2017 RESTRUCTURING ACTIVITIES.FY2018 EARNINGS PER SHARE VIEW $7.24, REVENUE VIEW $4.04 BILLION -- THOMSON REUTERS I/B/E/S.SEES FY18 GAAP EARNINGS PER SHARE BETWEEN LOSS OF $-0.08 TO PROFIT OF $0.26.  Full Article

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases
Wednesday, 24 Oct 2018 06:30am EDT 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND DICERNA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP RNAI THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.DICERNA PHARMACEUTICALS INC - DICERNA TO RECEIVE UPFRONT PAYMENT OF $22 MILLION AND EQUITY INVESTMENT OF $15 MILLION.DICERNA PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.DICERNA PHARMACEUTICALS - ALEXION MAKING A CONCURRENT $15 MILLION EQUITY INVESTMENT IN DICERNA AT A PREMIUM TO MARKET AS OF COLLABORATION EFFECTIVE DATE..DICERNA - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL DEVELOPMENT AND APPROVAL-RELATED MILESTONE PAYMENTS OF UP TO $105 MILLION PER TARGET.DICERNA PHARMACEUTICALS INC - COLLABORATION ALSO PROVIDES FOR SALES MILESTONES AND MID-SINGLE TO LOW-DOUBLE DIGIT ROYALTIES ON FUTURE PRODUCT SALES..  Full Article

FDA Accepts Priority Review Of ALXN1210 As Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria In The US
Monday, 20 Aug 2018 06:30am EDT 

Aug 20 (Reuters) - Alexion Pharmaceuticals Inc ::FDA ACCEPTS PRIORITY REVIEW OF ALXN1210 AS A TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN THE US.ALEXION PHARMACEUTICALS INC - FDA SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE OF FEBRUARY 18, 2019.ALEXION PHARMACEUTICALS - EU FILING ACCEPTED AND UNDER REVIEW FOR ALXN1210.  Full Article

Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.07
Thursday, 26 Jul 2018 06:30am EDT 

Alexion Pharmaceuticals Inc ::ALEXION REPORTS SECOND QUARTER 2018 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $2.07.Q2 GAAP LOSS PER SHARE $2.05.Q2 REVENUE $1.045 BILLION VERSUS I/B/E/S VIEW $977.7 MILLION.Q2 EARNINGS PER SHARE VIEW $1.70 -- THOMSON REUTERS I/B/E/S.UPDATED FULL YEAR 2018 GUIDANCE.SEES 2018 TOTAL REVENUES $3,980 MILLION TO $4,010 MILLION.SEES 2018 EARNINGS PER SHARE GAAP $1.25 TO $1.50.SEES 2018 EARNINGS PER SHARE NON-GAAP $7.00 TO $7.15.ALEXION EXPECTS TO INCUR ADDITIONAL RESTRUCTURING AND RELATED EXPENSES IN 2018 OF APPROXIMATELY $10 MILLION TO $60 MILLION.ALEXION PHARMACEUTICALS - MAY INCUR RESTRUCTURING EXPENSES THAT ARE MATERIALLY DIFFERENT FROM CURRENT ESTIMATE.FY2018 EARNINGS PER SHARE VIEW $7.03, REVENUE VIEW $4.00 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alexion offer for Wilson Therapeutics accepted
Friday, 25 May 2018 01:05am EDT 

May 25 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION OFFER FOR WILSON THERAPEUTICS ACCEPTED.ITS OFFER FOR SHARES IN WILSON BEEN ACCEPTED BY SHAREHOLDERS REPRESENTING 97.7 PCT OF TOTAL OF SHARES AND VOTES IN WILSON.ACQUISITION HAS ALSO BEEN APPROVED BY RELEVANT REGULATORY AUTHORITIES.TO GIVE WILSON'S SHAREHOLDERS ADDITIONAL TIME TO ACCEPT OFFER, CO HAS EXTENDED ACCEPTANCE PERIOD UNTIL JUNE 8, 2018.TO INITIATE COMPULSORY REDEMPTION PROCEEDINGS REGARDING REMAINING SHARES IN WILSON AND PROMOTE DELISTING FROM NASDAQ STOCKHOLM.OFFER FOR WILSON THERAPEUTICS MADE THROUGH A WHOLLY OWNED SUBSIDIARY OF CO.  Full Article

Alexion To Acquire Wilson Therapeutics
Wednesday, 11 Apr 2018 01:57am EDT 

April 11 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION TO ACQUIRE WILSON THERAPEUTICS.SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER.SAYS TOTAL EQUITY VALUE OF TRANSACTION AMOUNTS TO SEK 7,100 MILLION, OR APPROXIMATELY $855 MILLION.SAYS ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND..  Full Article

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
Monday, 2 Apr 2018 08:15am EDT 

April 2 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIM MILLER CONTINUES AS PRESIDENT AND ASSUMES CHIEF SCIENTIFIC OFFICER ROLE.THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC.  Full Article

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210
Thursday, 15 Mar 2018 06:30am EDT 

March 15 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS SHOWING SUCCESSFUL PHASE 3 CLINICAL STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS INC - SAFETY PROFILE OF ALXN1210 CONSISTENT WITH THAT SEEN FOR SOLIRIS.ALEXION PHARMACEUTICALS INC - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES, EUROPEAN UNION, AND JAPAN IN SECOND HALF OF 2018.ALEXION PHARMACEUTICALS INC - SAFETY PROFILE OF ALXN1210 CONSISTENT WITH THAT SEEN FOR SOLIRIS.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 ACHIEVED ALL FOUR KEY SECONDARY ENDPOINTS​.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 WAS GENERALLY WELL TOLERATED WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT SEEN FOR SOLIRIS​.ALEXION PHARMACEUTICALS - ALXN1210 ALSO ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF LACTATE DEHYDROGENASE NORMALIZATION.  Full Article

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.